奥妥珠单抗治疗儿童难治性肾病综合征的疗效与安全性
该回顾性队列研究纳入13例对利妥昔单抗(RTX)治疗效果不佳的原发性难治性肾病综合征(RNS)患儿,比较奥妥珠单抗(OBZ)治疗阶段与既往RTX治疗阶段的结局。结果显示OBZ阶段B细胞耗竭、尿蛋白缓解及激素和钙调神经磷酸酶抑制剂(CNI)停药时长均延长,年复发次数减少,未记录严重不良事件。
要点
- OBZ治疗后B细胞耗竭、尿蛋白缓解及激素和CNI停药时长均较RTX治疗后延长(均P<0.05)。
- OBZ治疗期间年复发次数低于RTX治疗期间[0(0,0.3)比1.9(1.4,2.6)次,Z=3.06,P=0.002]。
- 7例出现无症状低免疫球蛋白血症,无重度中性粒细胞减少、血小板减少或脏器损伤等严重不良事件。
核心结论
- 对于RTX治疗后B细胞耗竭不持久、病情频繁复发的儿童RNS,OBZ可实现更持久的B细胞耗竭,延长尿蛋白缓解时间,降低复发风险,并助力激素安全减量,可作为备选治疗方案。
研究设计与样本
- 回顾性队列研究,纳入2024年7月至2025年12月北京大学第一医院儿童医学中心诊治的13例原发性RNS患儿,均为RTX治疗效果不佳后采用OBZ治疗。
- 采用配对样本t检验、Wilcoxon符号秩检验、Mann-Whitney U检验、χ2检验或Fisher确切概率法,比较OBZ治疗阶段与既往RTX治疗阶段的结局。
主要发现
- 13例患儿中男10例、女3例,起病年龄(47±13)月龄,首次应用OBZ年龄(121±35)月龄;激素耐药型3例、激素敏感频复发型10例。
- OBZ治疗后B细胞耗竭时长、尿蛋白持续转阴时长、每年激素及CNI类药物停药时长均较RTX治疗后延长(均P<0.05)。
- 年复发次数OBZ治疗期间为0(0,0.3)次,RTX治疗期间为1.9(1.4,2.6)次,Z=3.06,P=0.002。
- 安全性方面,2例出现轻微输液反应(胃肠道不适、血压升高),减慢输注速度后缓解;1例因合并肺炎、中耳炎停止OBZ治疗;7例出现无症状低免疫球蛋白血症。
- 无重度中性粒细胞减少、血小板减少、脏器损伤等严重不良事件记录。
临床怎么用
- 对RTX治疗后B细胞耗竭不持久且频繁复发的儿童RNS,可考虑OBZ作为备选治疗方案,治疗中需监测B细胞耗竭、尿蛋白缓解及免疫球蛋白水平。
局限性
- 为单中心回顾性队列研究,样本量仅13例,结论需更大样本前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the efficacy and safety of obinutuzumab (OBZ) in children with refractory nephrotic syndrome (RNS) who have a poor response to rituximab (RTX) therapy. Methods: This retrospective cohort study enrolled children with primary RNS who received OBZ because of poor response to RTX at the Children's Medical Center of Peking University First Hospital from July 2024 to December 2025. For each patient, outcomes during the OBZ treatment phase were compared with those during their preceding RTX treatment phase. Comparative parameters included duration of sustained B-cell depletion, duration of urinary protein remission, tapering of glucocorticoids and immunosuppressants, relapse frequency, and adverse events. Paired t-test, Wilcoxon signed-rank test, Mann-Whitney U test, χ2 test and Fisher's exact test were adopted for statistical analysis according to the data type and distribution characteristics. Results: Thirteen children (10 males, 3 females) were enrolled. The age at disease onset was (47±13) months, and the age at first OBZ administration was (121±35) months. There were 3 cases of steroid-resistant and 10 cases of steroid-sensitive but frequently relapsing nephrotic syndrome. Compared with the RTX phase, the OBZ phase was associated with significantly longer durations of sustained B-cell depletion, sustained urinary protein remission, and annual glucocorticoid and calcineurin inhibitor (CNI) withdrawal (all P<0.05). The annual relapse frequency was significantly lower during OBZ treatment than during RTX treatment (0 (0, 0.3) vs. 1.9 (1.4, 2.6), Z=3.06, P=0.002). Regarding safety, 2 children developed mild transient infusion reactions (gastrointestinal discomfort and elevated blood pressure), which resolved with reduced infusion rate; 1 child discontinued OBZ due to concurrent pneumonia and otitis media; and 7 developed asymptomatic hypogammaglobulinemia. No severe adverse events, such as severe neutropenia, thrombocytopenia or organ dysfunction, were documented. Conclusions: For children with RNS who experience short B-cell depletion duration and frequent relapse after RTX therapy, OBZ provides more durable B-cell depletion, effectively prolongs urinary protein remission, reduces relapse risk, and facilitates safer glucocorticoid tapering. These findings suggest that OBZ may serve as a viable alternative therapeutic option for this specific pediatric population. 目的: 探讨奥妥珠单抗(OBZ)用于利妥昔单抗(RTX)治疗效果不佳的儿童难治性肾病综合征(RNS)的临床疗效及安全性。 方法: 回顾性队列研究。收集2024年7月至2025年12月北京大学第一医院儿童医学中心诊治的原发性RNS经RTX治疗效果不佳后采用OBZ治疗的患儿的临床资料,采用配对样本t检验、Wilcoxon符号秩检验、Mann-Whitney U检验、χ2检验或Fisher确切概率法比较分析患儿接受OBZ治疗后与RTX治疗后的B细胞耗竭持续时间、尿蛋白缓解时长、激素和免疫抑制剂减量情况、肾病复发次数及不良反应发生情况差异。 结果: 13例RNS患儿中男10例、女3例,起病年龄(47±13)月龄,首次应用OBZ年龄(121±35)月龄;其中激素耐药型肾病综合征3例、激素敏感频复发型10例。OBZ治疗后B细胞耗竭时长、尿蛋白持续转阴时长、每年激素及CNI类药物停药时长均较RTX治疗后延长(均P<0.05),平均每年肾病复发次数较RTX治疗期间减少[0(0,0.3)比1.9(1.4,2.6)次,Z=3.06,P=0.002]。OBZ输注过程中2例患儿出现轻微输液反应,表现为胃肠道不适、血压升高,经减慢输注速度后缓解;1例患儿因合并肺炎、中耳炎而停止OBZ治疗;7例出现无症状低免疫球蛋白血症;无重度中性粒细胞减少、血小板减少、脏器损伤等严重不良事件。 结论: 对于RTX治疗后B细胞耗竭不持久、病情频繁复发的儿童RNS,OBZ可实现更持久的B细胞耗竭,有效延长尿蛋白缓解时间,降低疾病复发风险,同时助力激素安全减量,可作为该类患儿的备选治疗方案。.
引用
- Liu XY, Zhuoga MZG, Bai W, et al. [Efficacy and safety of obinutuzumab in children with refractory nephrotic syndrome]. Zhonghua Er Ke Za Zhi. 2026. PMID: 42605085. doi:10.3760/cma.j.cn112140-20260608-00451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。